TY - JOUR
T1 - Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma
AU - Levin, Lynn I.
AU - Chang, Ellen T.
AU - Ambinder, Richard F.
AU - Lennette, Evelyne T.
AU - Rubertone, Mark V.
AU - Mann, Risa B.
AU - Borowitz, Michael
AU - Weir, Edward G.
AU - Abbondanzo, Susan L.
AU - Mueller, Nancy E.
PY - 2012/11/1
Y1 - 2012/11/1
N2 - An altered anti-Epstein-Barr virus (EBV) serologic profile preceding diagnosis is associated with an increased risk of Hodgkin lymphoma. It is unknown whether this atypical pattern predicts Hodgkin lymphoma risk further subdivided by determination of EBV in tumor cells. A nested case-control study of 128 incident Hodgkin lymphoma cases and 368 matched controls from active-duty military personnel with archived serum in the US Department of Defense Serum Repository was conducted to determine whether a panel of anti-EBV antibody titers differed in EBV+ and EBV- Hodgkin lymphoma. Among 40 EBV+ Hodgkin lymphoma cases and matched controls, statistically significant increased risks were associated with elevated anti-EBV VCA IgG antibody titers (relative risk = 3.1; 95% confidence interval [CI], 1.1-8.7), and an anti-EBNA-1/anti-EBNA-2 antibody ratio ≤ 1.0 versus > 1.0 (relative risk = 4.7; 95% CI, 1.6-13.8). In contrast, no significant associations were found among 88 EBV- Hodgkin lymphoma cases relative to their matched controls. In casecase analysis, EBV+ disease was significantly associated with a low anti-EBNA-1/ anti-EBNA-2 antibody ratio. This distinctive serologic response to EBV latent antigens, indicative of immune dysfunction in other clinical settings, is associated with an increased risk of developing EBV+ but not EBV- Hodgkin lymphoma.
AB - An altered anti-Epstein-Barr virus (EBV) serologic profile preceding diagnosis is associated with an increased risk of Hodgkin lymphoma. It is unknown whether this atypical pattern predicts Hodgkin lymphoma risk further subdivided by determination of EBV in tumor cells. A nested case-control study of 128 incident Hodgkin lymphoma cases and 368 matched controls from active-duty military personnel with archived serum in the US Department of Defense Serum Repository was conducted to determine whether a panel of anti-EBV antibody titers differed in EBV+ and EBV- Hodgkin lymphoma. Among 40 EBV+ Hodgkin lymphoma cases and matched controls, statistically significant increased risks were associated with elevated anti-EBV VCA IgG antibody titers (relative risk = 3.1; 95% confidence interval [CI], 1.1-8.7), and an anti-EBNA-1/anti-EBNA-2 antibody ratio ≤ 1.0 versus > 1.0 (relative risk = 4.7; 95% CI, 1.6-13.8). In contrast, no significant associations were found among 88 EBV- Hodgkin lymphoma cases relative to their matched controls. In casecase analysis, EBV+ disease was significantly associated with a low anti-EBNA-1/ anti-EBNA-2 antibody ratio. This distinctive serologic response to EBV latent antigens, indicative of immune dysfunction in other clinical settings, is associated with an increased risk of developing EBV+ but not EBV- Hodgkin lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=84868564575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868564575&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-12-390823
DO - 10.1182/blood-2011-12-390823
M3 - Article
C2 - 22972983
AN - SCOPUS:84868564575
SN - 0006-4971
VL - 120
SP - 3750
EP - 3755
JO - Blood
JF - Blood
IS - 18
ER -